Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-24T03:00:11.029Z Has data issue: false hasContentIssue false
  • English
  • Français

Application of Novel Biomaterials in Colloidal Drug Delivery Systems

Published online by Cambridge University Press:  29 November 2013

M.C. Garnett ,
S. Stolnik ,
S.E. Dunn ,
I. Armstrong ,
Wu Lin ,
E. Schacht ,
P. Ferutti ,
M. Vert ,
M.C. Davies  and
L. Illum
...Show all authors
Get access

Extract

The development of biomaterials to treat, repair, or reconstruct the human body is an increasingly important component of materials research. Collaboration between materials researchers and their industrial and clinical partners is essential for the development of this complex field. To demonstrate the importance of these interactions, two articles in this issue focus on advances in biomaterials relating to the use of colloidal systems for transport, drug delivery, and other medical applications. These articles were coordinated by Dominique Muster (Université Louis Pasteur, Strasbourg) and Franz Burny (Hôpital Erasme, Brussels). The following is the second of these two articles.

There are two important objectives in drug delivery research. The first is to maximize the effectiveness of drugs by increasing the amount of drug reaching the target tissue while sparing other tissues the deleterious effects of the drug. The second is to control the release of a drug, so that the period of optimal drug concentration in the target tissue is maximized. A numbe r of different Systems have been investigated to achieve these objectives, including soluble polymeric delivery Systems and a range of colloidal drug delivery forms such as liposomes, emulsions, micelles, microcapsules, microparticles, and nanoparticles. This article focuses on polymeric materials for the production of micro- or nanoparticle Systems for dru g delivery by injection, and their characterization and Performance in vivo.

Colloidal particles have a number of advantages as drug delivery Systems; they are easy to prepare, have the potential for high drug loading, and release of the drug can be controlled. However, without surface modification, colloidal particles are difficult to target because they are directed largely to the liver and spieen after intravenous injection. The reasons for this can be found in the context of the body's defenses. In order to protect against disease, the body has a complex System to ensure that invading microorganisms are identified and neutralized at the earliest possible opportunity. Most parasitic or invading organisms which pose a threat are particulate in form, and thus any colloidal drug delivery System will have to evade detection by these mechanisms in order to reach its target.

Type
Technical Features
Information
MRS Bulletin , Volume 24 , Issue 5 , May 1999 , pp. 49 - 56
Copyright
Copyright © Materials Research Society 1999

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Davis, S.S. and Illum, L., Biomaterials 9 (1988) p. 111.CrossRefGoogle Scholar
2.Davis, S.S. and Illum, L., “Microspheres as Drug Carriers,” in Drug Carrier Systems, edited by Roerdink, F.H.D. and Kroon, A.M. (John Wiley & Sons, New York, 1989) p. 131.Google Scholar
3.Illum, L., Hunneyball, I.M., and Davis, S.S., Int. J. Pharm. 2 (1986) p. 53.CrossRefGoogle Scholar
4.Stolnik, S., Garnett, M.C., Davies, M.C., Illum, L., Bousta, M., Vert, M., and Davis, S.S., Colloids Surf., A: Physicocliem. and Eng. Aspects 97 (1995) p. 235.CrossRefGoogle Scholar
5.Armstrong, T.I., Davies, M.C., and Illum, L., J. Drug Targeting 4 (1997) p. 389.CrossRefGoogle Scholar
6.Dunn, S.E., Coombes, A.G.A., Garnett, M.C., Davis, S.S., Davies, M.C., and Illum, L., J. Controlled Release 44 (1997) p. 65.CrossRefGoogle Scholar
7.Hagan, S.A., Coombes, A.G.A., Garnett, M.C., Dunn, S.E., Davies, M.C., Illum, L., Davis, S.S., Harding, S.E., Purkiss, S., and Gellert, P.R., Langmuir 12 (1996) p. 2153.CrossRefGoogle Scholar
8.Riley, T., Xiong, C.D., Hawley, A.E., Stolnik, S., Garnett, M.C., Tadros, Th.F., Illum, L., and Davis, S.S., “PLA-PEG Nanoparticles for Drug Delivery,” in Proc. 9th Int. Conf. on Surface and Colloid Science (Sofia, Bulgaria, July 6-12, 1997).Google Scholar
9.Riley, T., Washington, C., King, S.M., Heald, C.R., Stolnik, S., Garnett, M.C., Purkiss, S., Barlow, R.J., Gellert, P.R., Illum, L., and Davis, S.S., “PLA-PEG Nanoparticles for Drug Delivery: A Closer Examination of the PEG Corona,” in Proc. 2nd World Meet. APGI/APV (Paris, May 25–28, 1998).Google Scholar